What is Emmaus Life Sciences, Inc. (EMMA) stock price today?

Emmaus Life Sciences, Inc. (EMMA) is currently trading at $0.01, up 0.09% today.

What is EMMA P/E ratio?

Emmaus Life Sciences, Inc.'s P/E ratio is -0.09. This is below the market average, suggesting the stock may be undervalued relative to earnings.

What is EMMA return on equity (ROE)?

Emmaus Life Sciences, Inc.'s return on equity (ROE) is 13.78%, indicating how efficiently the company generates profit from shareholders' equity. This is above the market average.

What is Emmaus Life Sciences, Inc.'s market cap?

Emmaus Life Sciences, Inc. has a market capitalization of $824010.

OTC · Biotechnology

Emmaus Life Sciences, Inc. (EMMA) Stock

$0.01 +0.09% OTC: EMMA Healthcare

Valuation

Metric	Value
Price	$0.01
Market Cap	$824010
P/E Ratio	-0.09
P/B Ratio	-0.01
P/S Ratio	0.07
EPS (TTM)	$-0.12
52-Week High	$0.02
52-Week Low	$0.01
Dividend Yield	0.00%

Financials & Margins

Metric	Value
ROE	13.78%
ROA	-45.45%
ROCE	-0.75%
Gross Margin	93.35%
Operating Margin	3.22%
Net Margin	-70.65%
Debt/Equity	-0.47
Current Ratio	0.08

Annual Financials (USD)

Metric	2021	2022	2023	2024	2025
Revenue	$21.0M	$18.0M	$30.0M	$17.0M	$12.0M
Operating Profit	$-6.0M	$-7.0M	$4.0M	$-2.0M	$0
Net Profit	$-16.0M	$-11.0M	$-4.0M	$-6.0M	$-7.0M
EPS	$-0.32	$-0.21	$-0.07	$-0.10	$-0.12
Op Margin	-29.7%	-35.8%	12.0%	-11.4%	1.9%

Balance Sheet (USD)

Metric	2021	2022	2023	2024	2025
Total Assets	$57.0M	$48.0M	$35.0M	$24.0M	$21.0M
Total Liabilities	$78.0M	$82.0M	$83.0M	$80.0M	$85.0M
Cash	$2.0M	$2.0M	$3.0M	$1.0M	$2.0M
Borrowings	$30.0M	$31.0M	$33.0M	$33.0M	$33.0M

Cash Flow (USD)

Metric	2021	2022	2023	2024	2025
Operating Cash Flow	$-1.0M	$-5.0M	$-2.0M	$-2.0M	$0
Investing Cash Flow	$-13.0M	$-2.0M	$0	$2.0M	$2.0M
Financing Cash Flow	$0	$0	$0	$0	$0
Net Cash Flow	$0	$0	$1.0M	$-1.0M	$1.0M
Free Cash Flow	$-1.0M	$-5.0M	$-2.0M	$-2.0M	$0

Valuation & Return Ratios

Metric	Value
PEG Ratio	0.00
EV / EBITDA	-72.90
FCF Yield	-77.06%
Quick Ratio	0.06
Interest Coverage	0.05
Return 1Y	-23.27%
Return 3Y	-95.48%
Return 5Y	—

Peer Comparison

Ticker	Price	Change	P/E	Market Cap	Div Yield
BPTHBio-Path Holdings, Inc.	$0.04	+0.00%	-0.05	$355002	0.00%
HXBMHelix BioMedix, Inc.	$1.15	+12.75%	-0.47	$258414	0.00%
NPHCNutra Pharma Corp.	$0.00	—	-1.00	$2.15M	0.00%
NRXCFNeutriSci International Inc.	$0.00	—	-1.09	$653980	0.00%
ORGSOrgenesis Inc.	$0.11	-72.50%	-0.06	$568618	0.00%

About Emmaus Life Sciences, Inc.

Emmaus Life Sciences, Inc. is a commercial-stage biopharmaceutical enterprise dedicated to the discovery, development, commercialization, and sale of treatments and therapies, primarily addressing rare and orphan diseases across the United States and internationally. The company's flagship product is Endari, an L-glutamine oral powder designed to mitigate the acute complications associated with sickle cell disease in patients aged five and above, covering both pediatric and adult populations. Furthermore, Emmaus maintains a collaborative arrangement with Kainos Medicine, Inc. for the preclinical advancement of Kainos' proprietary IRAK4 inhibitor, KM10544, which is being explored as a potential anti-cancer therapeutic. Established in 2000 as Emmaus Holdings, Inc., the organization rebranded to Emmaus Life Sciences, Inc. in September 2011 and operates from its headquarters in Torrance, California.

Emmaus Life Sciences, Inc. is headquartered in US.

Emmaus Life Sciences, Inc. (EMMA) stock trades at $0.01 with a market capitalization of $824010. The stock is valued at a price-to-earnings (P/E) ratio of -0.09, price-to-book of -0.01, price-to-sales of 0.07. Over the past 52 weeks the stock has ranged between $0.01 and $0.02, and currently trades 50.0% below its 52-week high.

On profitability, Emmaus Life Sciences, Inc. generates a return on equity (ROE) of 13.78%, above the typical market average, return on capital employed of -0.75%, an operating margin of 3.22%, a net profit margin of -70.65%.

Official website: www.emmausmedical.com